Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, 6-Week, In-Patient Study to Assess Efficacy and Safety of HP-3070 in Subjects Diagnosed With Schizophrenia

NCT02876900 is registered in ClinicalTrials.gov with Noven Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02876900
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02876900 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, 6-Week, In-Patient Study to Assess Efficacy and Safety of HP-3070 in Subjects Diagnosed With Schizophrenia
Lead sponsor
Noven Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2016
Completion date
June 30, 2018
Enrollment
617 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia